Achieve Life Sciences Shares Rise After Complete Response Letter From FDA

Dow Jones

Jun 22

By Chris Wack

Achieve Life Sciences shares were 7.3% higher, at $5.21, after the company said it has received a complete response letter from the Food and Drug Administration regarding its New Drug Application for cytisinicline.

The late-stage specialty pharmaceutical company said the CRL relates to outstanding manufacturing-related observations from a current good manufacturing practice inspection of a third-party manufacturing facility and to final product labeling that wasn't completed by the FDA's action date.

The company said the FDA identified no deficiencies regarding the clinical efficacy or safety of cytisinicline.

The deficiencies cited in the CRL concern Achieve's prior third-party manufacturing facility, which received an Official Action Indicated classification from the FDA for general cGMP matters at the facility that aren't specific to cytisinicline.

Achieve intends to resubmit its NDA in the fourth quarter of 2026, naming Adare as its primary manufacturing partner, with potential FDA approval in the first half of 2027, followed by U.S. commercial launch.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 22, 2026 10:46 ET (14:46 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2645073013"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645073013\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645073013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645073013","market":"nz","top_or_hot":-1,"title":"Achieve Life Sciences Shares Rise After Complete Response Letter From FDA","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences shares were 7.3% higher, at $5.21, after the company said it has received a complete response letter from the Food and Drug Administration regarding its New Drug Application for cytisinicline. \n</p>\n<p>\n  The late-stage specialty pharmaceutical company said the CRL relates to outstanding manufacturing-related observations from a current good manufacturing practice inspection of a third-party manufacturing facility and to final product labeling that wasn't completed by the FDA's action date. \n</p>\n<p>\n  The company said the FDA identified no deficiencies regarding the clinical efficacy or safety of cytisinicline. \n</p>\n<p>\n  The deficiencies cited in the CRL concern Achieve's prior third-party manufacturing facility, which received an Official Action Indicated classification from the FDA for general cGMP matters at the facility that aren't specific to cytisinicline. \n</p>\n<p>\n  Achieve intends to resubmit its NDA in the fourth quarter of 2026, naming Adare as its primary manufacturing partner, with potential FDA approval in the first half of 2027, followed by U.S. commercial launch. \n</p>\n<p>\n  Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 10:46 ET (14:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Achieve Life Sciences Shares Rise After Complete Response Letter From FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAchieve Life Sciences Shares Rise After Complete Response Letter From FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-22 22:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences shares were 7.3% higher, at $5.21, after the company said it has received a complete response letter from the Food and Drug Administration regarding its New Drug Application for cytisinicline. \n</p>\n<p>\n  The late-stage specialty pharmaceutical company said the CRL relates to outstanding manufacturing-related observations from a current good manufacturing practice inspection of a third-party manufacturing facility and to final product labeling that wasn't completed by the FDA's action date. \n</p>\n<p>\n  The company said the FDA identified no deficiencies regarding the clinical efficacy or safety of cytisinicline. \n</p>\n<p>\n  The deficiencies cited in the CRL concern Achieve's prior third-party manufacturing facility, which received an Official Action Indicated classification from the FDA for general cGMP matters at the facility that aren't specific to cytisinicline. \n</p>\n<p>\n  Achieve intends to resubmit its NDA in the fourth quarter of 2026, naming Adare as its primary manufacturing partner, with potential FDA approval in the first half of 2027, followed by U.S. commercial launch. \n</p>\n<p>\n  Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 10:46 ET (14:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645073013","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645073013","pubTimestamp":1782139560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Achieve Life Sciences shares were 7.3% higher, at $5.21, after the company said it has received a complete response letter from the Food and Drug Administration regarding its New Drug Application for cytisinicline.The late-stage specialty pharmaceutical company said the CRL relates to outstanding manufacturing-related observations from a current good manufacturing practice inspection of a third-party manufacturing facility and to final product labeling that wasn't completed by the FDA's action date.The company said the FDA identified no deficiencies regarding the clinical efficacy or safety of cytisinicline.The deficiencies cited in the CRL concern Achieve's prior third-party manufacturing facility, which received an Official Action Indicated classification from the FDA for general cGMP matters at the facility that aren't specific to cytisinicline.Achieve intends to resubmit its NDA in the fourth quarter of 2026, naming Adare as its primary manufacturing partner, with potential FDA app","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","BK4139":"生物科技","ACHV":"Achieve Life Sciences, Inc.","BK4588":"碎股"},"translate_title":"FDA完成回复函后，Achieve Life Sciences股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"ACHV":0.9},"content_text":"By Chris Wack \n\n\n \n\n\nAchieve Life Sciences shares were 7.3% higher, at $5.21, after the company said it has received a complete response letter from the Food and Drug Administration regarding its New Drug Application for cytisinicline. \n\n\n  The late-stage specialty pharmaceutical company said the CRL relates to outstanding manufacturing-related observations from a current good manufacturing practice inspection of a third-party manufacturing facility and to final product labeling that wasn't completed by the FDA's action date. \n\n\n  The company said the FDA identified no deficiencies regarding the clinical efficacy or safety of cytisinicline. \n\n\n  The deficiencies cited in the CRL concern Achieve's prior third-party manufacturing facility, which received an Official Action Indicated classification from the FDA for general cGMP matters at the facility that aren't specific to cytisinicline. \n\n\n  Achieve intends to resubmit its NDA in the fourth quarter of 2026, naming Adare as its primary manufacturing partner, with potential FDA approval in the first half of 2027, followed by U.S. commercial launch. \n\n\n  Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 10:46 ET (14:46 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}